Recursion Pharmaceuticals announced that Sanofi has chosen their first development candidate from a joint immunology drug discovery collaboration, triggering a $10 million milestone payment to Recursion. This oral small molecule targets two inflammatory disease pathways and is expected to enter phase 1 clinical trials in 2027, funded and led by Sanofi. The collaboration combines Recursion's AI-driven drug design with Sanofi's expertise, aiming to deliver first-in-class treatments. Recursion has received $144 million in payments so far and may earn over $300 million more in milestones plus royalties if the drug is approved.
Recursion Pharmaceuticals (RXRX) trades at USD 3.76 on Pluang as of Oct 15, 2026 20:02 WIB, showing a modest 0.53% gain in the last day. The stock's market cap stands at $2.02 billion with a typical hold time of 22 days on the platform. This trading activity occurs alongside news of Sanofi selecting a development candidate from their collaboration, which may influence investor interest in RXRX shares.
Recursion Pharmaceuticals announced it priced an underwritten offering of 61.54 million Class A shares at $3.25 each, aiming to raise approximately $200 million before expenses. The funds will support its AI-enabled drug discovery platform and clinic...
Recursion Pharmaceuticals announced a $200 million oversubscribed follow-on stock offering backed by major healthcare investors. The company reported promising Phase 1b/2 data for REC-4881 showing significant and durable reductions in precancerous po...
